These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8875 related articles for article (PubMed ID: 156580)

  • 1. A phase I study of chlorozotocin (NSC 178248).
    Kovach JS; Moertel CG; Schutt AJ; Frytak S; O'Connell MJ; Rubin J; Ingle JN
    Cancer; 1979 Jun; 43(6):2189-96. PubMed ID: 156580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
    Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
    Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of chlorozotocin.
    Gralla RJ; Tan CT; Young CW
    Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.
    Panasci L; Comis R; Ginsberg S; Kohn L; Fitzpatrick A; Rubert M; Scalzo T
    Cancer Treat Rep; 1981; 65(7-8):647-50. PubMed ID: 6454483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
    Macdonald JS; Hoth D; Schein PS
    Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I studies on chlorozotocin.
    Hoth D; Woolley P; Green D; Macdonald J; Schein P
    Clin Pharmacol Ther; 1978 Jun; 23(6):712-22. PubMed ID: 148344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of dianhydrogalactitol (NSC-132313).
    Haas CD; Stephens RL; Hollister M; Hoogstraten B
    Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of chlorozotocin: single dose every six weeks.
    Taylor S; Belt RJ; Haas CD; Stephens RL; Hoogstraten B
    Cancer; 1980 Dec; 46(11):2365-8. PubMed ID: 6449279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of chlorozotocin in metastatic malignant melanoma.
    Hoth DF; Schein PS; Winokur S; Woolley PV; Robichaud K; Binder RB; Smith FP
    Cancer; 1980 Oct; 46(7):1544-7. PubMed ID: 6448088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical investigation of amonafide.
    Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
    J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
    Conley BA; O'Hara S; Wu S; Melink TJ; Parnes H; Pardoe E; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 1995; 37(1-2):139-49. PubMed ID: 7497583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase I clinical trial of recombinant DNA gamma interferon.
    Brown TD; Koeller J; Beougher K; Golando J; Bonnem EM; Spiegel RJ; Von Hoff DD
    J Clin Oncol; 1987 May; 5(5):790-8. PubMed ID: 3106584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of ametantrone acetate (NSC-287513).
    Gams RA; Ostroy F; Bender JF; Grillo-López AJ
    Invest New Drugs; 1985; 3(4):383-8. PubMed ID: 4086246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
    Van Amburg AL; Presant CA; Burns D
    Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 444.